Eight-Weeks Of Treatment With Talnetant In Subjects With Irritable Bowel Syndrome (IBS)

Status:
Completed

Trial end date:
2005-07-01

Target enrollment:

Participant gender:

This study will evaluate the effectiveness and safety of the investigational drug talnetant in treating subjects with irritable bowel syndrome (IBS).

Phase 2

GlaxoSmithKline